CheckMate143 (NCT02017717), a randomized controlled clinical trial comparing Nivolumab (PD-1 antibody) with Bevacizumab in recurrent glioblastoma (rGBM) patients, is the first trial launched in the United States (27). This evidence concerns the gene PDCD1 and glioblastoma.